| __timestamp | BioCryst Pharmaceuticals, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 17986000 |
| Thursday, January 1, 2015 | 13047000 | 32480000 |
| Friday, January 1, 2016 | 11253000 | 68081000 |
| Sunday, January 1, 2017 | 13933000 | 169906000 |
| Monday, January 1, 2018 | 29514000 | 248932000 |
| Tuesday, January 1, 2019 | 37121000 | 354100000 |
| Wednesday, January 1, 2020 | 67929000 | 433300000 |
| Friday, January 1, 2021 | 118818000 | 583300000 |
| Saturday, January 1, 2022 | 159371000 | 752700000 |
| Sunday, January 1, 2023 | 213894000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Unleashing insights
In the competitive world of biotechnology, managing operational costs is crucial for success. Over the past decade, Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting strategies in their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Neurocrine Biosciences saw a staggering 4,800% increase in SG&A expenses, reflecting its aggressive expansion and investment in operational infrastructure. In contrast, BioCryst Pharmaceuticals experienced a more modest 2,800% rise, indicating a more conservative approach.
By 2023, Neurocrine's SG&A expenses were nearly four times higher than BioCryst's, suggesting a focus on scaling operations and market penetration. This divergence highlights the strategic choices companies make in balancing growth with cost efficiency. As investors and stakeholders analyze these trends, understanding the implications of SG&A efficiency becomes paramount in predicting future performance.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.